Suggested remit: To appraise the clinical and cost effectiveness of niraparib within its marketing authorisation as maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after complete or partial response to first-line platinum-based chemotherapy.
 
Status In progress
Process STA 2018
ID number 1680

Provisional Schedule

Committee meeting: 1 10 November 2020
Expected publication 10 February 2021

Project Team

Project lead Jeremy Powell

Email enquiries

Evidence Review Group / Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ

Consultees

Companies sponsors GlaxoSmithKline (niraparib)
Others Department of Health and Social Care
  NHS England
  NHS Bassetlaw CCG
  NHS Fylde & Wyre CCG
  Welsh Government
Patient carer groups Black Health Agency
  Cancer Black Care
  Cancer Equality
  Cancer 52
  Eve Appeal
  Gynae C
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Muslim Council of Britain
  Ovacome
  Ovarian Cancer Action
  Robin Cancer Trust
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Target Ovarian Cancer
  Tenovus Cancer Care
  Wellbeing of Women
  Women’s Health Concern
Professional groups Association of Cancer Physicians
  British Geriatrics Society
  British Gynaecological Cancer Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Society of Urogynaecology
  Cancer Research UK
  National Forum of Gynaecological Oncology Nurses
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Obstetricians & Gynaecologists
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society

Commentators

Comparator companies none
General commentators Allied Health Professionals Federation
  All Wales Therapeutics and Toxicology Centre
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Gynaecological Cancer Group
  Genomics England
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research
  Ovarian & Prostate Cancer Research Trust

Timeline

Key events during the development of the guidance:

Date Update
11 March 2020 Invitation to participate
24 January 2020 The Department for Health and Social Care has asked NICE to conduct an appraisal of niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during mid-March 2020 when we will write to you about how you can get involved
12 November 2019 - 10 December 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
18 March 2019 In progress. DHSC Referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance